PHOENIX, AZ--(Marketwire - November 01, 2011) - INSYS Therapeutics (PINKSHEETS: NEOL) announces the addition of Shawn Simon as Vice President of Sales, and Becky Gamble as Vice President of Managed Markets to their commercial product team. They will lead the development and management of the sales team in preparation for the launch of INSYS’ breakthrough cancer pain product candidate, Subsys® fentanyl sublingual spray.
Shawn is a highly accomplished entrepreneurial Sales Executive and brings 30 plus years of industry experience including sales, marketing, and managed care experience to INSYS. Over the last two decades Shawn built and led the cardiovascular and neuroscience specialty teams at Bristol-Myers Squibb where he later ran a $1.5B brand portfolio. Most recently at Sanofi-Aventis, Shawn integrated and led their oncology specialty teams and later became Vice President of Managed Care for National, Regional and Specialty GPO/LTC/VADOD Accounts. Shawn holds a BS Degree from State University of New York at Fredonia and has completed the Executive Leadership Programs at Americas Health Insurance Plans, Kellogg, University Michigan, MIT and Anderson School of Business.
Becky Gamble brings 23 years of industry experience including managed care, sales management and marketing to INSYS. The most recent 17 years of Becky’s career have been entrenched in the reimbursement arena. Becky was recognized as an industry leader in 2005 as one of the Healthcare Business Women Association’s “Rising Stars.” Prior to joining INSYS, Becky was the Specialty Business Unit Head for Shionogi Pharma and prior to that led Shionogi’s Managed Markets organization. Her tenure in managed markets also spans Solvay Pharmaceuticals and Roche Labs. Becky is a graduate of Auburn University with a BS BA in International Business.
Michael Babich, President and CEO of INSYS, adds, “We are delighted to add these two talented individuals to our team as we look to commercialize Subsys with our own dedicated sales force. They will be of incredible value to the company and we are excited to have the pieces in place that are necessary for a successful product launch.”
About INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products that address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders. We develop new formulations and delivery methods for existing drugs in order to achieve enhanced efficacy, faster onset of action, reduced side effects, convenient delivery and increased patient compliance. Our drug development programs are based on existing compounds with known or proven safety, efficacy and commercialization histories. We are focused on leveraging our expertise in the expanding synthetic cannabinoid derivatives and specialized opioid markets to build a portfolio of proprietary products that address the limitations of existing therapies.
Media Contacts:
Michael Babich
(602) 910-2617
